Pangea Bio strives to improve the likelihood of success and reduce timelines in developing new medicines for patients. We combine advanced Central Nervous System (CNS) drug development with AI to drive our scalable pipeline of nature-inspired drugs. We optimize our success rates by starting our small molecule drug discovery programs with compounds found in natural sources that possess prior evidence of safety and efficacy in humans.
Our lead compound OT-003
Our lead asset OT-003 is a proprietary small molecule with compelling data across a range of cellular and in vivo models in our indication areas. We are building a pipeline of NCEs based on OT-003’s mechanism, to treat a wide range of neurological disorders.
AI-Discovery engine
We perform AI-driven discovery to scale our pipeline of new lead molecules as well as to deliver novel discoveries for external partners.
Our Impact Work
It is part of Pangea’s mission to preserve ethnobotanical knowledge and habitats. We are committed to the Nagoya Protocol on Access and Benefit Sharing and we are working to fulfill the highest ESG standards.
